About Neuronal vesicle trafficking-associated protein 1
Neuronal vesicle trafficking-associated protein 1 (NSG1) is a protein
from Homo sapiens identified by UniProt accession
P42857, 185 residues long.
MolForge cross-references it against 0 known binders and
145 disease associations.
Target properties
| Protein name | Neuronal vesicle trafficking-associated protein 1 |
|---|
| UniProt accession | P42857 |
|---|
| Gene | NSG1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 185 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (145)
Diseases linked to this target (Open Targets).
- hair colour measurement · score 0.32
- neurodegenerative disease · score 0.27
- hair color · score 0.23
- adolescent idiopathic scoliosis · score 0.19
- DNA methylation · score 0.16
- esophageal squamous cell carcinoma · score 0.09
- diabetic maculopathy · score 0.07
- macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss · score 0.06
- Blackfan-Diamond anemia · score 0.06
- neutrophil immunodeficiency syndrome · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P42857-F1 | alphafold | PREDICTED | 60.78 | — |
Amino-acid sequence (185 residues)
MVKLGNNFAE KGTKQPLLED GFDTIPLMTP LDVNQLQFPP PDKVVVKTKT EYEPDRKKGK ARPPQIAEFT VSITEGVTER FKVSVLVLFA LAFLTCVVFL VVYKVYKYDR ACPDGFVLKN TQCIPEGLES YYAEQDSSAR EKFYTVINHY NLAKQSITRS VSPWMSVLSE EKLSEQETEA AEKSA
Explore Neuronal vesicle trafficking-associated protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets